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Abstract
Diabetes, in particular type 2, is associated with an increased incidence of cancer. Although the
mortality attributable to cancer in type 2 diabetes is overshadowed by that due to cardiovascular
disease, emerging data from epidemiologic studies suggest that insulin therapy may confer added risk
for cancer, perhaps mediated by signaling through the IGF-1 (insulin-like growth factor-1) receptor.
Co-administered metformin seems to mitigate the risk associated with insulin. A recent series of
publications in Diabetologia addresses the possibility that glargine, the most widely used long-acting
insulin analogue, may confer a greater risk than other insulin preparations, particularly for breast
cancer. This has led to a heated controversy. Despite this, there is a consensus that the currently
available data are not conclusive and should not be the basis for any change in practice. Further
studies and more thorough surveillance of cancer in diabetes are needed to address this important
issue.
Introduction and context
The associations between diabetes and cancer have
been the subject of debate for over a century. The length
of this debate suggests, perhaps, that any such associa-
tions are relatively weak, and it is safe to say that most
practicing diabetologists do not view cancer as a specific,
diabetes-associated risk in day-to-day practice. That
diabetes is not more clearly associated with cancer is
surprising, since diabetes may be viewed as a disease
of increased intracellular oxidative stress, as well as
accelerated ‘biochemical aging’ caused by the accu-
mulation of ‘advanced glycation end-products’ (AGEs)
onproteinsandothermacromolecules(reviewedin[1]).
An additional concern is the role of insulin, which, in
variousforms,isincreasinglyusedinthemanagementof
type 2 diabetes, a condition that is now epidemic
worldwide. Specifically, the ability of insulin to bind
and activate the insulin-like growth factor-1 (IGF-1)
receptor has raised concerns that it may promote the
growth of nascent malignancies and even the establish-
ment of new ones. Such concerns are supported by
animal and cell culture studies.
With this background, there has been a recent surge in
interest in the role of diabetes, insulin therapy, and
specifically the effects of newer forms of insulin in
promoting cancer. Recent rigorous epidemiologic studies
have confirmed that type 2 diabetes does indeed confer
increased risk for certain types of malignancies, in
particular breast [2], colon [3,4], and pancreatic [5,6]
tumors. Many patients with type 2 diabetes eventually
require insulin, and the long-acting insulin analogue,
glargine, is one of the most commonly used agents.
Several recent studies have demonstrated the potential
mitogenic and anti-apoptotic effects of glargine on
cultured cancer cells, and have implicated activation of
the IGF-1 pathway [7,8]. However, the clinical implica-
tions remain controversial, particularly when studies
pertaining to untransformed cells did not support any
mitogenic potential [9]. In addition, according to some
authors [10,11], glargine compared with human insulin
does not seem to display increased mitogenic effects,
despite its higher affinity for the IGF-1 receptor [10];
rather, any type of insulin has the potential to promote
growth in cancer cells, especially if administered at
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now is whether glargine is associated with increased
cancer risk compared with other commonly used forms
of insulin. This question has come to the fore with the
publication of several studies in Diabetologia [12-15],
which will be reviewed briefly here.
Recent advances
The epidemiologic study that initiated the recent debate
was performed in Germany [12] and suggested a specific
cancer risk associated with glargine. Based upon the
mixed opinions of six reviewers, the editors of Diabeto-
logia, the journal to which it was submitted, commis-
sioned three additional studies [13-15], aiming to
confirm or refute its findings.
In the initial study, Hemkens et al. [12] followed 127,031
German patients who were being treated with human
insulin and human insulin analogues (aspart, lispro, or
glargine) over a mean of 1.6 years between January 1998
and June 2005. Those on two insulin analogues or a
combination of human insulin and an analogue were
excluded from the analysis. Patients with known or
suspected malignant disease within 3 years prior to study
start were also excluded. The primary outcome was
occurrence of a malignant neoplasm, and the secondary
outcome was all-cause mortality. The gross malignancy
incidence rates for human insulin, aspart, lispro, and
glargine were 2.50, 2.16, 2.13, and 2.14 per 100 patient-
years, respectively, in the unadjusted analysis. However,
when the data were adjusted for daily insulin dose,
glargine was found to be associated with a greater risk of
malignancy, and the risk was incremental with higher
glargine doses when compared with human insulin
{adjusted hazard ratio [HR] of 1.09 for a daily dose of
10 IU [95% confidence interval (CI) 1.00-1.19], 1.19 for
a daily dose of 30 IU [95% CI 1.10-1.30], and 1.31 for
a daily dose of 50 IU [95% CI 1.20-1.42]}. Aspart and
lispro were not associated with an increased risk for
cancer compared with human insulin. In addition,
regardless of the type of insulin, higher doses and longer
duration of exposure increased the risk of malignancy.
Finally, the mean insulin dose until occurrence of a
neoplasm (cumulative dose divided by time until an
event) was significantly lower for glargine (25.9 IU/day)
than for human insulin, aspart, and lispro (43.8, 38.9,
and 36.2 IU/day, respectively). The major weaknesses of
the study included the fact that patients were not
allocated to treatment groups in a prospective manner
and that insulin dose was calculated during follow-up
from mean values, and not determined at baseline. In
addition, the exclusion of patients on combination
insulin therapy may not reflect common practice, in
which patients are typically on basal/bolus regimens
requiring the use of different types of insulin. Finally, the
duration of diabetes, as well as smoking status, body
mass index (BMI), and other potential confounding
factors were not taken into account.
The three additional, commissioned studies were pub-
lished in the same issue of Diabetologia. In Sweden,
Jonasson and colleagues [13] evaluated 114,842 patients
with diabetes on insulin and noted that women on
glargine alone, but not glargine combined with other
types of insulin, had a higher risk of breast cancer than
women on other types of insulin (HR adjusted for age,
smoking, BMI, and other confounding factors was 1.97,
95% CI 1.29-3.00). However, this increased risk was not
associated with an increased mortality rate; instead, all-
cause mortality was actually decreased in women on
glargine alone versus women on other types of insulin
(relative risk [RR] 0.83, 95% CI 0.71-0.96). The associa-
tions with other malignancies such as prostate and
gastrointestinal tumors did not reach statistical signifi-
cance. No analysis taking into account insulin dose was
possible in this study, and therefore the incremental risk
conferred by higher doses as observed by Hemkens et al.
[12] could not be supported or refuted. The short
duration of exposure and observation as well as the
lack of data on how much insulin the patients were
taking limit the strength of the conclusions.
In a study in Scotland, no increased risk of total or site-
specific cancer associated with overall glargine use was
found in a cohort of 12,852 patients followed for 4 years
[14]; in particular, no increase in breast cancer risk (HR
1.49, 95% CI 0.79-2.83) was found. However, exclusive
use of glargine did seem to confer higher risk (adjusted
HR 3.39, 95% CI 1.46-7.85), but the number of cases
was small (six events). In addition, glargine-only users
tended to be older, were more likely to be women, and to
have a higher BMI, reflecting a baseline imbalance. In
addition, the effect of concomitantly administered drugs
was not taken in account. Finally, the restricted use of
glargine in Scotland may have contributed to a skewing
of the results, since there were a limited number of
patients taking this form of insulin.
In a UK general practice setting, Currie et al. [15] studied
62,809 patients with diabetes on metformin, sulfony-
lurea monotherapy, a combination of both, or insulin
therapy. The latter were further divided into glargine-
treated versus other human insulin-treated (long-acting,
biphasic, and biphasic analogue). The results indicated
that any type of insulin therapy increased the risk of
occurrence of solid tumors and that concomitant
metformin therapy attenuated this effect. Indeed, the
adjusted HRs relative to metformin monotherapy were
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combination, 1.36 (95% CI 1.19-1.54) for sulfonylurea
alone, and 1.42 (95% CI 1.27-1.60) for insulin-based
therapies. Concomitant metformin therapy decreased
the risk of malignancy associated with insulin by 46%
(HR 0.54, 95% CI 0.43-0.66). When compared with
glargine, other human insulins displayed comparable
rates, suggesting no added risk attributable to glargine
(adjusted HR 1.24, 95% CI 0.90-1.17 for basal human
insulin; HR 0.88, 95% CI 0.66-1.19 for biphasic human
insulin; and HR 1.02, 95% CI 0.76-1.37 for analogue
biphasic insulin). Malignancies that had the strongest
association with insulin therapy compared with metfor-
min were colorectal (HR 1.69, 95% CI 1.23-2.33) and
pancreatic (HR 4.63, 95% CI 2.64-8.10) tumors. Breast
and prostate cancer risks did not seem to be affected by
treatment with insulin or insulin secretagogues, and a
prior history of solid tumor strongly increased the overall
risk (HR 3.86, 95% CI 3.46-4.31).
In a letter published in a subsequent issue of Diabetologia,
Rosenstock et al. [16], reported a study of glargine versus
neutral protamine Hagedorn (NPH) insulin in type 2
diabetes patients randomly assigned to one insulin or
the other for over 4 years. Although malignancy risk was
not a primary endpoint for the study, no increased cancer
risk with glargine compared to NPH was found (RR 0.90,
95% CI 0.64-1.26).
Home and Lagarenne [17], using the sanofi-aventis
‘Pharmacovigilance database’ for all randomized
company-sponsoredclinicaltrials,publishedasystematic
review of 31 trials comparing glargine to other agents
(NPH for most studies). No evidence for an increased
risk of malignancy attributable to glargine was found
(RR 0.90, 95% CI 0.60-1.36). All but one of these studies
lasted less than 12 months (on average, 6 months), so
their major limitation was the short duration of exposure
and follow-up. Indeed, the majority of reported cases of
malignancy were derived from the study of Rosenstock
and colleagues [16], discussed above, in which follow-up
exceeded 4 years.
Finally, a meta-analysis comparing cancer risk associated
with another new, long-acting insulin, insulin detemir,
versus NPH and glargine was performed. It used data
from randomized controlled trials sponsored by Novo
Nordisk (Bagsvaerd, Denmark) and found comparable
malignancy risks associated with detemir and glargine in
the five trials that compared both drugs. However, the
number of events was very small (n = 8; event rate per
100 exposure-years = 0.87 for detemir, and n = 8; event
rate per 100 exposure-years = 1.27 for glargine) [18].
The debate has, not surprisingly, raised considerable
controversy. The issues are highly emotive: cancer and
diabetes eventually affect a large proportion of the
world’s population. In addition, there are enormous
financial implications surrounding the controversy, and
unfortunately, complex issues tend to be oversimplified
and are often sensationalized. Either a diagnosis of
cancer or the institution of insulin therapy for diabetes
provokes great anxiety in many people. Criticism of the
publication of the Diabetologia papers came in the
correspondence section of The Lancet, where Pocock
and Smeeth [19] raised concerns regarding the quality of
the statistical analyses and contended that these analy-
tical flaws, especially in the German paper, had raised
unsubstantiated anxieties. They criticized the Swedish
study for its finding of an association of insulin glargine
with breast cancer [13], arguing that the latter was not a
‘pre-defined site for analysis’ but rather a secondary
finding ultimately not ‘confirmed by the Scottish study’
[14] (the latter did find an increased risk of breast cancer
associated with the exclusive use of glargine, but only
affecting very few, older patients). Further criticism came
in an editorial by Garg, Hirsch, and Skyler [20] in
Diabetes Technology and Therapeutics, questioning the
motivations behind the German study and raising
concerns similar to those brought up by Pocock and
Smeeth [19]. This paper also emphasized the lack of
evidence of an increased overall cancer risk associated
with glargine based on the Swedish, Scottish, and UK
studies, concluding that ‘glargine use should not be
discontinued based on unsubstantiated allegations.’ The
letter of Pocock and Smeeth elicited a prompt response
from the editor of Diabetologia [21]. The editor, while
acknowledging the imperfections of the studies (which
he had already discussed in detail in an accompanying
editorial [22]), argued that the epidemiologic data
cannot and should not be dismissed, especially when
considered in the context of animal and cell culture
work, but rather should generate further research to
define risk. Indeed, in his initial editorial on the subject
[22], he had earlier stated that ‘the evidence presented
in this set of papers is sufficient to establish that there is
a case to answer, but is entirely insufficient to bring
a verdict.’ At least on the latter conclusion, all parties
agreed.
Implications for clinical practice
These thought-provoking studies, although inconclusive,
do raise concerns about the long-term effects of diabetes
itself, insulin treatment, and specifically, glargine, on
cancer development. It must be remembered that the
greatly increased mortality among patients with diabetes
has little to do with cancer, but instead is related to
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of good glycemic control is likely to support extensive
use of insulin. All are agreed that the current evidence
does not warrant any change in clinical practice,
specifically with regard to the use of glargine. Further
research will need to address the relationship between
diabetes, insulin, insulin analogues and secretagogues,
and cancer. It will also explore potentially protective
effects of metformin and perhaps the most tantalizing
question: why is diabetes not more strongly associated
with cancer?
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